Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab plus doxorubicin rechallenge in pretreated advanced soft tissue sarcoma
2018-001124-20Phase 2Terminated
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaratumab in soft tissue sarcoma (STS), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Progression-free survival rate at 3 months (PFSR3). Started Jun 2018; status: terminated.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2018-001124-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001124-20.